Gilead Sciences C-Level Executives Sell Millions in Shares Under 10b5-1 Plan

Gilead Sciences, Inc. (NASDAQ: GILD) announced that on January 15, 2026, Chief Operating Officer Johanna Mercier and Chief Financial Officer Andrew Dickinson each sold roughly 3,000 shares at $124.31 per share, generating about $373,000 apiece (approximately ₩490 million). Both transactions were made under pre-arranged Rule 10b5-1 trading plans. After the sales, Mercier still holds over 100,000 shares and Dickinson around 150,000 shares.

On January 20, outside director Jeffrey Bluestone exercised options on 5,000 shares and immediately sold the same number of shares at $123.50 each, raising about $618,000 (roughly ₩800 million). He continues to own common stock and additional option rights valued at approximately $1.1 million (about ₩1.4 billion).

The company noted that it will maintain its investor outreach, with management scheduled to present corporate strategy and pipeline updates at the J.P. Morgan Healthcare Conference on January 12, 2025. Materials released in 2025 emphasize revenue growth driven by the HIV therapy Biktarvy, alongside data on long-acting HIV treatment and prevention candidates, underscoring Gilead’s reinforced core portfolio.

Headquartered in California, Gilead Sciences is a leading biopharmaceutical firm specializing in treatments for HIV, hepatitis, COVID-19, cancer and inflammatory diseases. Its flagship products include the HIV therapy Biktarvy, hepatitis C regimens and the COVID-19 antiviral remdesivir. For over 30 years, Gilead has ranked among the world’s top antiviral drug companies by revenue.